▶주메뉴 바로가기

▶본문 바로가기

The Korea Herald
검색폼

THE INVESTOR
March 19, 2024

Bio

[EXCLUSIVE] Celltrion files suits against Genentech for Herceptin, Rituxan patents

  • PUBLISHED :January 19, 2018 - 15:26
  • UPDATED :January 21, 2018 - 18:53
  • 폰트작게
  • 폰트크게
  • facebook
  • sms
  • print

[THE INVESTOR] Korean pharmaceutical firm Celltrion has filed two lawsuits challenging the validity of Genentech’s patents for its blockbuster therapies Herceptin and Rituxan as the Korean company seeks to launch its biosimilar versions in the US.

The suits were filed on Jan. 11 in a California district court seeking declaratory judgment that 38 patents relating to Genentech’s breast cancer therapy Herceptin and 37 patents relating to lymphoma treatment Rituxan are non-infringing and invalid.




The move came as Celltrion is awaiting approval from the US Food and Drug Administration to market the company’s two biosimilar products -- Herzuma, a copycat of Herceptin and Truxima, the biosimilar of Rituxan.

“Genentech has rested on a complex series of patents from two dozen patent families. As Celltrion has already demonstrated to Genentech, these allegations are wrong and the panoply of vague allegations are simply intended to interfere with Celltrion and Teva’s entry into the market,” read the complaint. 

Genentech joined the Roche pharmaceutical group in 2009.

By Park Han-na (hnpark@heraldcorp.com)

EDITOR'S PICKS